Immunogenicity and protective potential of a mucosal protein-only vaccine candidate for tuberculosis - Takeaways - MDSpire

Immunogenicity and protective potential of a mucosal protein-only vaccine candidate for tuberculosis

  • By

  • AC Tran

  • MY Kim

  • EJ Vergara

  • MJ Paul

  • D Burnsall

  • M Das

  • JE Pearl

  • AM Cooper

  • Rajko Reljic

  • June 23, 2026

  • 0 min

Share

  • 1

    The BCG vaccine is limited in preventing pulmonary TB in adults due to its systemic administration route, which fails to induce strong mucosal immunity.

  • 2

    The novel TB-PCF vaccine platform combines Mycobacterium tuberculosis antigens with Cholera Toxin B subunit to enhance immune responses.

  • 3

    TB-PCF vaccination elicited significant antigen-specific antibody responses and polyfunctional Th1 and Th17 responses in mice.

  • 4

    In vivo challenge tests showed only BCG vaccination significantly reduced lung bacterial burden compared to TB-PCF.

  • 5

    The study suggests TB-PCF may serve as a platform for exploring diverse antigen combinations for improved mucosal TB vaccination.

Original Source(s)

Immunogenicity and protective potential of a mucosal protein-only vaccine candidate for tuberculosis

  • by AC Tran, MY Kim, EJ Vergara, MJ Paul, D Burnsall, M Das, JE Pearl, AM Cooper, Rajko Reljic

  • June 23, 2026

Related Content

First HIV-Positive-to-HIV-Positive Lung Transplant Reported

The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.

Protective outcomes of high-affinity monoclonal antibodies against drug-resistant plague strains

Clinical characteristics, predictive factors, and therapeutic outcomes of mycoplasma pneumoniae pneumonia with pleural effusion in children: a retrospective cohort study